Trial intelligence / Profile preview

AK105 plus carboplatin/paclitaxel vs placebo in squamous non-small cell lung cancer

CTR20182025Phase 3Completed

Sponsor
Akeso, Inc.
Start
Nov 2018
Modality
Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

A Phase 3 trial of penpulimab in Pulmonary squamous cell carcinoma, sponsored by Akeso, Inc.. Started Nov 2018; status: completed.

02

Drugs

penpulimab
03

Conditions

Pulmonary squamous cell carcinoma

Beyond the preview

Go deeper on CTR20182025.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20182025.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call